{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001005509"],"host":["EGA"],"description":["EGA study EGAS00001005509"],"dataset_title":["A Single-cell Atlas of Progressive TKI Resistance in Chronic Myeloid Leukemia"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["Myelogenous Leukemias, Myelocytic, Myelogenous, leukemia, Chronic Myelocytic Leukemia, dTAF[[II]]230, TAF[[II]]250, d230, Chronic Granulocytic Leukemia, Granulocytic Leukemias, Philadelphia Positive, Chronic Myeloid Leukemia, Myeloid, Chronic Myelocytic, TAF200, Ph1-Positive Myelogenous Leukemia, Myelocytic Leukemia, l(3)84Ab, dTAFII250, BG:DS00004.13, chronic granulocytic leukaemia, Philadelphia-Positive, Philadelphia-Positive Myeloid Leukemias, TAFII-250, TAF250/230, EfW1, Cell, Leukemias, chronic, dTAF230, dmTAF[[II]]230, Ph1-Positive, CML, Ph1-Positive Myeloid Leukemias, TAFII250, chronic myelogenous, Chronic myelogenous leukemia, chronic myelogenous leukemia, dmTAF1, Taf230, p230, Philadelphia-Positive Myeloid, resistance, Myeloid Leukemias, TAF[[II]]250/230, TFIID, Ph1 Positive, atypical, Philadelphia-Positive Myeloid Leukemia, TAF250, Chronic Myelocytic Leukemias, Taf[[II]]250, Chronic Granulocytic Leukemias, Chronic granulocytic leukemia, Taf200, chronic myeloid, Leukemia, dTAF[[II]]250, TAF[[II]]230, Chronic Granulocytic, Chronic Myelogenous, Chronic Myelogenous Leukemia, TFIID TAF250, Chronic Myeloid Leukemias, cel, cell, C1, Granulocytic Leukemia, Ph1-Positive Myelogenous, Chronic Myelogenous Leukemias, Taf1p, Myelogenous Leukemia, TAF[II]250, Ph1-Positive Myeloid, CG17603, TAF[[II]], Atlases, Granulocytic, dTAF250, DmelCG17603, chronic granulocytic leukemia, Taf250, Ph1-Positive Myeloid., Ph1-Positive Myelogenous Leukemias, SR3-5, chronic myelogenous leukaemia, CML - chronic Myelogenous Leukemia, Myeloid Leukemia, Myelocytic Leukemias, chronic myeloid leukaemia, Ph1-Positive Myeloid Leukemia, Chronic, TAF, TAF230, Chronic Myeloid, TAF1"],"description_synonyms":["NK Cell, Patient-Relevant Outcome, Biological Markers, Viral Marker, Antemortem Diagnosis, Rehabilitation Outcome, CD159A, insensitive, Inflammations, Surrogate Endpoints, Natural Killer Cell, Laboratory, 14-3-3-e, Feature, hspc, 143E_DROME, Biochemical, myc-B, Endpoint, DmelCG10798, MYC, Myc, Serum, Diagnosis, HSPC, B430311C09Rik, psma7, SUB, dmTAF[[II]]230, Personal, Laboratory Markers, c-MYC, c-Myc, diseases, DmelCG12298, EG:BACN5I9.1, RC6-1, Biological, responsivity, symptoms, ARC, SCRAMBLED, diseases and disorders, myc, KIF20A, D14-3-3e, Natural Killer, Clinical Effectiveness, Psychological, treatment, CG31196, c-myc, human disease, inflammatory response, TFIID TAF250, cel, Natural, dm/dMyc, anon-WO02059370.52, C1, par-5, C6, Social, allergic reaction, Effectiveness, Immune, CD159a, Markers, Viral Markers, disease management, Therapies, Treatment Effectiveness, Homo sapiens disease, Outcome, Social Power, Treatment Efficacy, Diagnose, Power, Therapy, screening, dTAF[[II]]230, Viral, Data Set, 14-3-3e, Surrogate Endpoint, dmyc1, AU016757, STRUBBELIG, TAF200, Biochemical Markers, Psychological Powers, TAFII-250, TAF250/230, Biologic Marker, anon-WO0172774.141, CD34, Diagnoses, TAFII250, Postmortem, Screenings, Dm, Marker, Examinations and Diagnoses, NOP, DmelCG31196, Diseases, Postmortem Diagnosis, mMyc, activation, Patient Relevant Outcome, Diagnoses and Examination, AU040960, l(1)G0354, Postmortem Diagnoses, mass cytometry assay, d14-3-3epsilon, resistant, End Points, Outcomes, l(1)G0359, signs, SR3-9, Immunologic, d-myc, Laboratory Marker, Features, CG17603, TAF[[II]], 14-3-3EPSILON, Treatments, D-Myc, Myc2, Atlases, 14-3-3, disease, Niard, large granular lymphocyte, myc2, Taf250, Specificity and Sensitivity, Biochemical Marker, SR3-5, Cells, 1433epsilon, G0 phase, null cell, dMyc1, Powers, MRTL, Innate, rc6-1, TAF230, AT1G11140, CG10798, Psychological Power, Patient-Relevant, Inflammatory Response, Natural Killer Cells, other disease, d230, dm/myc, Professional Power, Clinical Markers, Clinical Marker, l(1)G0139, D14-3-3epsilon, hematopoietic progenitor cell antigen CD34, dTAFII250, EfW1, dMyc, dMYC, CG12298, Surrogate End Points, Surrogate Markers, anon-WO03040301.171, MYCC, eps, dmTAF1, Taf230, sensitive, resistance, Mass, c-myc II, Screening, disease or disorder, Nop30, bHLHe57, Antemortem, Rehabilitation, sensitivity, CyTOF, Phenomenography, TAF250, reactivity, Biomarker, Taf200, dTAF[[II]]250, Clinical, l(3)j2B10, cell, mei-1794, Biological Marker, Dmyc, DMYc, inflammation, Taf1p, Diagnoses and Examinations, EK3-5, non-neoplastic, BHLHE39, dTAF250, Immunologic Markers, Nird, RNCMYC, Innate Inflammatory Response, NKG2, PAR-5, Sensitivity, disorder, SRF9, Characteristics, TAF, 14-3-3-epsilon, bHLHe39, Immunologic Marker, dmyc, Par-5, Biologic, Patient-Relevant Outcomes, Antemortem Diagnoses, TAF[[II]]250, findings, NK Cells, CT24092, Immune Markers., Serum Markers, disorders, cell cycle quiescence, End Point, NKG2B, l(3)84Ab, psma4-B, NKG2A, BG:DS00004.13, medical condition, Examination and Diagnoses, Cell, Immune Marker, dTAF230, STRUBBELIG-RECEPTOR FAMILY 9, 14-3-3omicron, Characteristic, Mass Screenings, Surrogate End Point, p230, TAF[[II]]250/230, 14-3-30epsilon, TFIID, condition, Professional, Clinical Efficacy, 14-3-3 epsilon, NK, Biologic Markers, Taf[[II]]250, Serum Marker, TAF[[II]]230, Surrogate, Dub, Endpoints, Specificity, xapc7, TAF[II]250, Surrogate Marker, Su(Raf)3B, Personal Power, DmelCG17603, Efficacy, Killer Cell, Therapeutic, Innate Inflammatory Responses, XAPC7, Power (Psychology), PAR5, Treatment, response, NK cell, T19D16.8, SCM, TAF1"],"additional_accession":[]},"is_claimable":false,"name":"A Single-cell Atlas of Progressive TKI Resistance in Chronic Myeloid Leukemia","description":"High-dimensional scRNA seq and CyTOF were used to identify features predictive  of treatment outcome at diagnosis. An optimal TKI response was characterised by erythroid lineage skewing of the CD34+ HSPC compartment. While TKI-resistant CP was reminiscent of a BC-like state, where HSPCs were enriched for inflammation, stemness and quiescence. We designed a machine-learning approach which assessed the prognostic potential of all 32 sub-populations of our scRNA seq dataset. LSCs and NK populations harboured the highest prognostic power at diagnosis. Within the LSCs, erythroid lineage priming and MYC activation were features of an optimal and poor TKI responses, respectively. With the NK cell compartment, apart from a higher abundance of NK cells in TKI optimal responders, a memory-like HLA-DR+ adaptive NK  and KLRC1+ NK populations were hallmarks of an optimal and poor TKI responses, respectively.  Mechanistically, both cell intrinsic and extrinsic mechanisms contributed towards the higher sensitivity of EPs to TKI therapy. In summary, our high-dimensional single-cell atlas of TKI resistance highlights pivotal transcriptional features associated with TKI-resistance disease, some of which have the potential to be exploited as biomarkers.","dates":{"updated":"2023-11-16 11:25:17"},"accession":"EGAS00001005509","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001007946","EGAC00001002245"]}}